New Two-Drug strategy aims to save insulin cells in young diabetics
NCT ID NCT06455319
Summary
This study is testing if a two-step treatment can help young people recently diagnosed with type 1 diabetes. First, some will receive a low-dose immune therapy (ATG) or a placebo. Then, all will have the option to take a blood pressure drug (verapamil) for a second year. The main goal is to see if this approach helps the body continue making its own insulin for longer, which could make diabetes easier to manage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Davis Center for Diabetes
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Florida
RECRUITINGGainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.